Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.

ESMO open - 1 Jun 2022

Hyung J, Lee H, Jin H, Lee S, Lee H J, Gong G, Song T J, Lee S S, Hwang D W, Kim S C, Jeong J H, Ryoo B-Y, Kim K, Yoo C

Abstract excerpt

BACKGROUND: A comprehensive analysis of peripheral immune cell phenotypes and tumor immune-gene expression profiles in locally advanced pancreatic cancer patients treated with neoadjuvant chemotherapy in a phase II clinical trial was carried out. METHODS: Patients were treated with neoadjuvant modified folinic acid, fluorouracil, irinotecan hydrochloride, oxaliplatin (mFOLFIRINOX) followed by surgery and adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Leucovorin

Share to Oxaliplatin

Share to Pancreatic Neoplasms

Share to Transcriptome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35576696
DOI: 10.1016/j.esmoop.2022.100484
PMCID: PMC9271485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.PMID 35576696Read ↗

Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancerSemantic proximity Read ↗

A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read ↗

Prognostic value of eight immune gene signatures in pancreatic cancer patientsSemantic proximity Read ↗

Novel drug resistance- and macrophage polarization-related molecular subtyping and prognostic signature for pancreatic adenocarcinomaSemantic proximity Read ↗

Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validationSemantic proximity Read ↗

Immune Subtyping for Pancreatic Cancer with Implication in Clinical Outcomes and Improving ImmunotherapySemantic proximity Read ↗

A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Prognostic Significance and Immune Infiltration of Microenvironment‐related Signatures in Pancreatic CancerSemantic proximity Read ↗

An immune-related microRNA signature prognostic model for pancreatic carcinoma and association with immune microenvironmentSemantic proximity Read ↗

The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasomeSemantic proximity Read ↗

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read ↗

High expression of TLR2 influenced immune infiltration in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.